FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Ursula Creutzig

Research Profile

Disorders

Living Beings

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Drug Resistance, Neoplasm

Phenomena

Recurrence

Co-author Network

Publications

TOP 3
Gertjan J L Kaspers; Guy G Leverger; Alexei Maschan; Bassem I Razzouk; Dirk Reinhardt; Carmelo Rizzari; Petr Smisek; Owen Smith; Batia Stark; Rienk Y J Tamminga; Martin Zimmermann; Olga Aleinikova; Hortensia Armendariz; Yves Bertrand; Michael Dworzak; Brenda E S Gibson; Shau-Yin Ha; Henrik Hasle; Liisa Hovi; Ursula Creutzig
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Mahban Irandoust; G J L Kaspers; Pamela Kearns; Dirk Reinhardt; Karin Schornagel; Edwin Sonneveld; Peter J Valk; Ellen M van Beek; Arjan A van de Loosdrecht; Mercan Akyuz; Julian Alvarez Zarate; A J F Broekhuizen; Jacqueline Cloos; Eva A Coenen; Ursula Creutzig; Eveline S J M de Bont; Ruud Delwel; Isabelle Hubeek; Marry M van den Heuvel-Eibrink; Christian M Zwaan; Timo K van den Berg
Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.
Ursula Creutzig; Eveline S J M de Bont; Michael Dworzak; Brenda Gibson; Jochen Harbott; Henrik Hasle; Donna Johnston; G J L Kaspers; Akitoshi Kinoshita; Thomas Lehrnbecher; Guy Leverger; Ester Mejstrikova; Soheil Meshinchi; Andrea Pession; Susana C Raimondi; Dirk Reinhardt; Jan Stary; Lillian Sung; Marry M van den Heuvel-Eibrink; Christian M Zwaan; Souichi Adachi
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Ursula Creutzig (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Gertjan J L Kaspers; Guy G Leverger; Alexei Maschan; Bassem I Razzouk; Dirk Reinhardt; Carmelo Rizzari; Petr Smisek; Owen Smith; Batia Stark; Rienk Y J Tamminga; Martin Zimmermann; Olga Aleinikova; Hortensia Armendariz; Yves Bertrand; Michael Dworzak; Brenda E S Gibson; Shau-Yin Ha; Henrik Hasle; Liisa Hovi; Ursula Creutzig
Improved outcome in pediatric relapsed acute myeloid leukemia: results of a randomized trial on liposomal daunorubicin by the International BFM Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2013;31(5):599-607.
2013: Mahban Irandoust; G J L Kaspers; Pamela Kearns; Dirk Reinhardt; Karin Schornagel; Edwin Sonneveld; Peter J Valk; Ellen M van Beek; Arjan A van de Loosdrecht; Mercan Akyuz; Julian Alvarez Zarate; A J F Broekhuizen; Jacqueline Cloos; Eva A Coenen; Ursula Creutzig; Eveline S J M de Bont; Ruud Delwel; Isabelle Hubeek; Marry M van den Heuvel-Eibrink; Christian M Zwaan; Timo K van den Berg
Engagement of SIRPα inhibits growth and induces programmed cell death in acute myeloid leukemia cells.
PloS one 2013;8(1):e52143.
2012: Ursula Creutzig; Eveline S J M de Bont; Michael Dworzak; Brenda Gibson; Jochen Harbott; Henrik Hasle; Donna Johnston; G J L Kaspers; Akitoshi Kinoshita; Thomas Lehrnbecher; Guy Leverger; Ester Mejstrikova; Soheil Meshinchi; Andrea Pession; Susana C Raimondi; Dirk Reinhardt; Jan Stary; Lillian Sung; Marry M van den Heuvel-Eibrink; Christian M Zwaan; Souichi Adachi
Diagnosis and management of acute myeloid leukemia in children and adolescents: recommendations from an international expert panel.
Blood 2012;120(16):3187-205.
2012: Eva A Coenen; Ursula Creutzig; Rolf Marschalek; Claus Meyer; Rob Pieters; Jutta Bradtke; Christian M Zwaan; Marry M van den Heuvel-Eibrink
Abl-interactor 2 (ABI2): a novel MLL translocation partner in acute myeloid leukemia.
Leukemia research 2012;36(5):e113-5.
2012: Dirk Reinhardt; K Reinhardt; C Rössig; A Sander; A Sauerbrey; Arend von Stackelberg; Ursula Creutzig; Jan-Henning Klusmann; C Neuhoff; Arnulf Pekrun; A Kolenova
[GATA1-mutation associated leukemia in children with trisomy 21 mosaic].
Klinische Pädiatrie 2012;224(3):153-5.
2012: Ursula Creutzig; Michael Dworzak; Bernhard Kremens; T Lehrnbecher; J-P Bourquin; Annette Sander; I Schmid; J Starý; Daniel Steinbach; C von Neuhoff; Arend von Stackelberg; Josef Vormoor; Martin Zimmermann; Dirk Reinhardt
Favorable outcome in infants with AML after intensive first- and second-line treatment: an AML-BFM study group report.
Leukemia 2012;26(4):654-61.
2012: I H I M Hollink; Rob Pieters; Dirk Reinhardt; Jan Trka; Marry M van den Heuvel-Eibrink; L J Verboon; J Wang; P Zhang; S T C J M Arentsen-Peters; Ursula Creutzig; A A Danen-van Oorschot; V de Haas; Q Feng; Christian M Zwaan
Low frequency of DNMT3A mutations in pediatric AML, and the identification of the OCI-AML3 cell line as an in vitro model.
Leukemia 2012;26(2):371-3.
2011: Ursula Creutzig; Michael Dworzak; Jean-Pierre Bourquin; Selim Corbacioglu; Annette Sander; André Schrauder; Jan Stary; Andrea Teigler-Schlegel; Christine von Neuhoff; Martin Zimmermann; Dirk Reinhardt
Second induction with high-dose cytarabine and mitoxantrone: different impact on pediatric AML patients with t(8;21) and with inv(16).
Blood 2011;118(20):5409-15.
2011: F Damm; V de Haas; Arnold Ganser; Michael Heuser; I Hollink; Jan-Henning Klusmann; J Krauter; Dirk Reinhardt; K Reinhardt; F Thol; Marry M van den Heuvel-Eibrink; Martin Zimmermann; Christian M Zwaan; Ursula Creutzig; C Thiede
Prevalence and prognostic value of IDH1 and IDH2 mutations in childhood AML: a study of the AML-BFM and DCOG study groups.
Leukemia 2011;25(11):1704-10.
2011: Brian Balgobind; Andre Baruchel; Berna Beverloo; Jean-Michel Cayuela; Jacqueline Cloos; Ursula Creutzig; Valerie de Haas; Jochen Harbott; Iris H I M Hollink; G J L Kaspers; Rob Pieters; Dirk Reinhardt; Jan Stary; Anne R M von Bergh; Zuzana Zemanova; Martin Zimmermann; Christian M Zwaan; Susan T C J M Arentsen-Peters; Marry M van den Heuvel-Eibrink
Integrative analysis of type-I and type-II aberrations underscores the genetic heterogeneity of pediatric acute myeloid leukemia.
Haematologica 2011;96(10):1478-87.
2011: Iris H I M Hollink; Gert-Jan J L Kaspers; Jenny E Kuipers; Rob Pieters; Marta Pratcorona; Dirk Reinhardt; Edwin Sonneveld; Jan Trka; Peter J M Valk; Marry M van den Heuvel-Eibrink; Janneke F van Galen; Martin Zimmermann; Saman Abbas; Susan T C J M Arentsen-Peters; Andre Baruchel; Berna Beverloo; Ursula Creutzig; Christian M Zwaan
NUP98/NSD1 characterizes a novel poor prognostic group in acute myeloid leukemia with a distinct HOX gene expression pattern.
Blood 2011;118(13):3645-56.
2010: Brian Balgobind; Christian M Zwaan; Dirk Reinhardt; T J C M Arentsen-Peters; I H I M Hollink; V de Haas; G J L Kaspers; Eveline S J M de Bont; A Baruchel; Jan Stary; Claus Meyer; Rolf Marschalek; Ursula Creutzig; Monique L den Boer; Rob Pieters; Marry M van den Heuvel-Eibrink
High BRE expression in pediatric MLL-rearranged AML is associated with favorable outcome.
Leukemia 2010;24(12):2048-55.
2010: Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Martin Zimmermann; Brian Balgobind; Susan T C J M Arentsen-Peters; Marielle Alders; Andre Willasch; Gert-Jan J L Kaspers; Jan Trka; Andre Baruchel; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; C Michel Zwaan
No prognostic impact of the WT1 gene single nucleotide polymorphism rs16754 in pediatric acute myeloid leukemia.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(28):e523-6; author reply e527-e528.
2010: Bianca F Goemans; Christian M Zwaan; Jacqueline Cloos; Desiree de Lange; Anne H Loonen; Dirk Reinhardt; Karel Hählen; Brenda E S Gibson; Ursula Creutzig; G J L Kaspers
FLT3 and KIT mutated pediatric acute myeloid leukemia (AML) samples are sensitive in vitro to the tyrosine kinase inhibitor SU11657.
Leukemia research 2010;34(10):1302-7.
2010: Denise Niewerth; Ursula Creutzig; Marc Bierings; G J L Kaspers
A review on allogeneic stem cell transplantation for newly diagnosed pediatric acute myeloid leukemia.
Blood 2010;116(13):2205-14.
2010: Annette Sander; Martin Zimmermann; Michael Dworzak; Gudrun Fleischhack; C von Neuhoff; Dirk Reinhardt; G J L Kaspers; Ursula Creutzig
Consequent and intensified relapse therapy improved survival in pediatric AML: results of relapse treatment in 379 patients of three consecutive AML-BFM trials.
Leukemia 2010;24(8):1422-8.
2010: Christine von Neuhoff; Dirk Reinhardt; Annette Sander; Martin Zimmermann; Jutta Bradtke; David R Betts; Zuzana Zemanova; Jan Stary; Jean-Pierre Bourquin; Oskar A Haas; Michael Dworzak; Ursula Creutzig
Prognostic impact of specific chromosomal aberrations in a large group of pediatric patients with acute myeloid leukemia treated uniformly according to trial AML-BFM 98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(16):2682-9.
2010: Stephanie Ehlers; Christin Herbst; Martin Zimmermann; Nicole Scharn; Manuela Germeshausen; Nils von neuhoff; Christian Michel Zwaan; Katarina Reinhardt; Iris H Hollink; Jan-Henning Klusmann; Thomas Lehrnbecher; Silja Roettgers; Jan Stary; Michael Dworzak; Karl Welte; Ursula Creutzig; Dirk Reinhardt
Granulocyte colony-stimulating factor (G-CSF) treatment of childhood acute myeloid leukemias that overexpress the differentiation-defective G-CSF receptor isoform IV is associated with a higher incidence of relapse.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(15):2591-7.
2010: Brian Balgobind; S Lugthart; I H Hollink; S T J C M Arentsen-Peters; Elisabeth R van Wering; Siebold S N de Graaf; Dirk Reinhardt; Ursula Creutzig; G J L Kaspers; E S J M de Bont; Jan Stary; Jan Trka; M Zimmermann; Berna Beverloo; Rob Pieters; Ruud Delwel; Christian M Zwaan; Marry M van den Heuvel-Eibrink
EVI1 overexpression in distinct subtypes of pediatric acute myeloid leukemia.
Leukemia 2010;24(5):942-9.
2010: Heidrun Gerr; Martin Zimmermann; Martin Schrappe; Michael Dworzak; Wolf-Dieter Ludwig; Jutta Bradtke; Anja Moericke; Richard Schabath; Ursula Creutzig; Dirk Reinhardt
Acute leukaemias of ambiguous lineage in children: characterization, prognosis and therapy recommendations.
British journal of haematology 2010;149(1):84-92.
2010: Christian M Zwaan; Dirk Reinhardt; Martin Zimmerman; Henrik Hasle; Jan Stary; Batia Stark; Michael Dworzak; Ursula Creutzig; G J L Kaspers
Salvage treatment for children with refractory first or second relapse of acute myeloid leukaemia with gemtuzumab ozogamicin: results of a phase II study.
British journal of haematology 2010;148(5):768-76.
2009: Thomas Lehrnbecher; Marie-Chantal Ethier; Theoklis Zaoutis; Ursula Creutzig; Alan Gamis; Dirk Reinhardt; Richard Aplenc; Lillian Sung
International variations in infection supportive care practices for paediatric patients with acute myeloid leukaemia.
British journal of haematology 2009;147(1):125-8.
2009: Iris H I M Hollink; Marry M van den Heuvel-Eibrink; Martin Zimmermann; Brian Balgobind; Susan T C J M Arentsen-Peters; Marielle Alders; Andre Willasch; G J L Kaspers; Jan Trka; Andre Baruchel; Siebold S N de Graaf; Ursula Creutzig; Rob Pieters; Dirk Reinhardt; Christian M Zwaan
Clinical relevance of Wilms tumor 1 gene mutations in childhood acute myeloid leukemia.
Blood 2009;113(23):5951-60.
2009: Thomas Lehrnbecher; Ursula Creutzig
Myeloid growth factors as anti-infective measures in children with leukemia and lymphoma.
Expert review of hematology 2009;2(2):159-72.
2008: Dorle Messerer; Jutta Engel; Joerg Hasford; Markus Schaich; Gerhard Ehninger; Cristina Sauerland; Thomas Büchner; Andrea Schumacher; Rainer Krahl; Dietger Niederwieser; Jürgen Krauter; Arnold Ganser; Ursula Creutzig; Hartmut Döhner; Richard F Schlenk
Impact of different post-remission strategies on quality of life in patients with acute myeloid leukemia.
Haematologica 2008;93(6):826-33.
2008: Jan-Henning Klusmann; Ursula Creutzig; Martin Zimmermann; Michael Dworzak; Norbert Jorch; Claudia Langebrake; Arnulf Pekrun; Katarina Macakova-Reinhardt; Dirk Reinhardt
Treatment and prognostic impact of transient leukemia in neonates with Down syndrome.
Blood 2008;111(6):2991-8.
2008: Lüder Hinrich Meyer; Manon Queudeville; Sarah M Eckhoff; Ursula Creutzig; Dirk Reinhardt; Leonid Karawajew; Wolf-Dieter Ludwig; Karsten Stahnke; Klaus-Michael Debatin
Intact apoptosis signaling in myeloid leukemia cells determines treatment outcome in childhood AML.
Blood 2008;111(5):2899-903.
2008: Hendrik J M de Jonge; Alida C Weidenaar; Arja ter Elst; H Marike Boezen; Frank J G Scherpen; Jessica C A Bouma-Ter Steege; G J L Kaspers; Bianca Goemans; Ursula Creutzig; Martin Zimmermann; Willem A Kamps; Eveline S J M de Bont
Endogenous vascular endothelial growth factor-C expression is associated with decreased drug responsiveness in childhood acute myeloid leukemia.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(3):924-30.
2008: Ursula Creutzig; Thomas Büchner; Maria C Sauerland; Martin Zimmermann; Dirk Reinhardt; Hartmut Döhner; Richard F Schlenk
Significance of age in acute myeloid leukemia patients younger than 30 years: a common analysis of the pediatric trials AML-BFM 93/98 and the adult trials AMLCG 92/99 and AMLSG HD93/98A.
Cancer 2008;112(3):562-71.
2007: Thomas Lehrnbecher; J Kaiser; Domenica Varwig; J Ritter; A H Groll; Ursula Creutzig; Thomas Klingebiel; Dirk Schwabe
Antifungal usage in children undergoing intensive treatment for acute myeloid leukemia: analysis of the multicenter clinical trial AML-BFM 93.
European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology 2007;26(10):735-8.
2007: Ursula Creutzig; Sylke Diekamp; Martin Zimmermann; Dirk Reinhardt
Longitudinal evaluation of early and late anthracycline cardiotoxicity in children with AML.
Pediatric blood & cancer 2007;48(7):651-62.
2007: Thomas Lehrnbecher; Martin Zimmermann; Dirk Reinhardt; Michael Dworzak; Jan Stary; Ursula Creutzig
Prophylactic human granulocyte colony-stimulating factor after induction therapy in pediatric acute myeloid leukemia.
Blood 2007;109(3):936-43.
2006: G J L Kaspers; Dirk Reinhardt; Gudrun Fleischhack; H Armendariz; Batia Stark; Christian M Zwaan; Martin Zimmermann; Ursula Creutzig
Low efficacy of methotrexate in childhood acute myeloid leukemia (AML): single-agent therapeutic window study in relapsed AML.
Pediatric blood & cancer 2006;47(5):539-42.
2006: Ursula Creutzig; Martin Zimmermann; Thomas Lehrnbecher; Norbert Graf; Johann Hermann; Charlotte M Niemeyer; Alfred Reiter; Jörg Ritter; Michael Dworzak; Jan Stary; Dirk Reinhardt
Less toxicity by optimizing chemotherapy, but not by addition of granulocyte colony-stimulating factor in children and adolescents with acute myeloid leukemia: results of AML-BFM 98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(27):4499-506.
2006: Claudia Langebrake; Ursula Creutzig; Michael Dworzak; Ondrej Hrusak; Ester Mejstrikova; Frank Griesinger; Martin Zimmermann; Dirk Reinhardt
Residual disease monitoring in childhood acute myeloid leukemia by multiparameter flow cytometry: the MRD-AML-BFM Study Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3686-92.
2006: Jacqueline Cloos; Bianca Goemans; Corine J Hess; Johan W van Oostveen; Quinten Waisfisz; S Corthals; Desiree de Lange; N Boeckx; Karel Hählen; Dirk Reinhardt; Ursula Creutzig; Gerrit J Schuurhuis; Ch M Zwaan; G J L Kaspers
Stability and prognostic influence of FLT3 mutations in paired initial and relapsed AML samples.
Leukemia 2006;20(7):1217-20.
2006: Christian M Zwaan; Monique L den Boer; Karin M Kazemier; Karel Hählen; Anne H Loonen; Dirk Reinhardt; Ursula Creutzig; G J L Kaspers; Rob Pieters
Does modulation of P-glycoprotein have clinical relevance in pediatric acute myeloid leukemia?
Blood 2006;107(12):4975-6; author reply 4976-7.
2006: Isabelle Hubeek; Godefridus J Peters; Richard Broekhuizen; Christian M Zwaan; Patricia Kaaijk; Elisabeth S van Wering; Brenda E S Gibson; Ursula Creutzig; Gritta E Janka-Schaub; Monique L den Boer; Rob Pieters; G J L Kaspers
In vitro sensitivity and cross-resistance to deoxynucleoside analogs in childhood acute leukemia.
Haematologica 2006;91(1):17-23.
2006: Ronald W Stam; Isabelle Hubeek; Monique L den Boer; J G C A M Buijs-Gladdines; Ursula Creutzig; G J L Kaspers; Rob Pieters
MLL gene rearrangements have no direct impact on Ara-C sensitivity in infant acute lymphoblastic leukemia and childhood M4/M5 acute myeloid leukemia.
Leukemia 2006;20(1):179-82.
2005: Isabelle Hubeek; Ronald W Stam; Godefridus J Peters; Richard Broekhuizen; Jules P P Meijerink; Elisabeth R van Wering; Brenda E S Gibson; Ursula Creutzig; Christian M Zwaan; Jacqueline Cloos; Dirk J Kuik; Rob Pieters; G J L Kaspers
The human equilibrative nucleoside transporter 1 mediates in vitro cytarabine sensitivity in childhood acute myeloid leukaemia.
British journal of cancer 2005;93(12):1388-94.
2005: Ursula Creutzig; M Zimmermann; J Ritter; Dirk Reinhardt; J Hermann; Günter Henze; H Jürgens; H Kabisch; Alfred Reiter; Hansjörg Riehm; Helmut Gadner; Günther Schellong
Treatment strategies and long-term results in paediatric patients treated in four consecutive AML-BFM trials.
Leukemia 2005;19(12):2030-42.
2005: Bianca Goemans; Christian M Zwaan; Amy Harlow; Anne H Loonen; Brenda E S Gibson; Karel Hählen; Dirk Reinhardt; Ursula Creutzig; Michael C Heinrich; G J L Kaspers
In vitro profiling of the sensitivity of pediatric leukemia cells to tipifarnib: identification of T-cell ALL and FAB M5 AML as the most sensitive subsets.
Blood 2005;106(10):3532-7.
2005: Isabelle Hubeek; Godefridus J Peters; A J F Broekhuizen; J Sargent; Brenda E S Gibson; Ursula Creutzig; G J L Kaspers
Potentiation of in vitro ara-C cytotoxicity by ribonucleotide reductase inhibitors, cyclin-dependent kinase modulators and the DNA repair inhibitor aphidicolin in paediatric acute myeloid leukaemia.
British journal of haematology 2005;131(2):219-22.
2005: Thomas Lehrnbecher; Toralf Bernig; Mitra Hanisch; Ulrike Koehl; M Behl; Dirk Reinhardt; Ursula Creutzig; Thomas Klingebiel; STEPHEN CHANOCK; Dirk Schwabe
Common genetic variants in the interleukin-6 and chitotriosidase genes are associated with the risk for serious infection in children undergoing therapy for acute myeloid leukemia.
Leukemia 2005;19(10):1745-50.
2005: Bianca Goemans; Christian M Zwaan; Simone Martinelli; Patina Harrell; Desiree de Lange; Claudio Carta; Dirk Reinhardt; Karel Hählen; Ursula Creutzig; Marco Tartaglia; Michael C Heinrich; G J L Kaspers
Differences in the prevalence of PTPN11 mutations in FAB M5 paediatric acute myeloid leukaemia.
British journal of haematology 2005;130(5):801-3.
2005: Bianca Goemans; Christian M Zwaan; M Miller; Martin Zimmermann; Amy Harlow; Soheil Meshinchi; Anne H Loonen; Karel Hählen; Dirk Reinhardt; Ursula Creutzig; G J L Kaspers; Michael C Heinrich
Mutations in KIT and RAS are frequent events in pediatric core-binding factor acute myeloid leukemia.
Leukemia 2005;19(9):1536-42.
2005: Ursula Creutzig; Dirk Reinhardt; Sylke Diekamp; Michael Dworzak; Jan Stary; Martin Zimmermann
AML patients with Down syndrome have a high cure rate with AML-BFM therapy with reduced dose intensity.
Leukemia 2005;19(8):1355-60.
2005: Dirk Reinhardt; Sylke Diekamp; Claudia Langebrake; J Ritter; Jan Stary; Michael Dworzak; André Schrauder; Martin Zimmermann; Gudrun Fleischhack; W-D Ludwig; Jochen Harbott; Ursula Creutzig
Acute megakaryoblastic leukemia in children and adolescents, excluding Down's syndrome: improved outcome with intensified induction treatment.
Leukemia 2005;19(8):1495-6.
2005: Isabelle Hubeek; Godefridus J Peters; A J F Broekhuizen; Iannis Talianidis; Jennifer Sigmond; Brenda E S Gibson; Ursula Creutzig; G Giaccone; G J L Kaspers
Immunocytochemical detection of deoxycytidine kinase in haematological malignancies and solid tumours.
Journal of clinical pathology 2005;58(7):695-9.
2005: Claudia Langebrake; Ursula Creutzig; Dirk Reinhardt
Immunophenotype of Down syndrome acute myeloid leukemia and transient myeloproliferative disease differs significantly from other diseases with morphologically identical or similar blasts.
Klinische Pädiatrie 2005;217(3):126-34.
2005: Claudia Langebrake; Iris Brinkmann; Andrea Teigler-Schlegel; Ursula Creutzig; Frank Griesinger; Ulrike Puhlmann; Dirk Reinhardt
Immunophenotypic differences between diagnosis and relapse in childhood AML: Implications for MRD monitoring.
Cytometry. Part B, Clinical cytometry 2005;63(1):1-9.
2005: Ulrike Puhlmann; Christina Ziemann; Gudrun Ruedell; Hagen Vorwerk; Dirk Schaefer; Claudia Langebrake; Peter Schuermann; Ursula Creutzig; Dirk Reinhardt
Impact of the cyclooxygenase system on doxorubicin-induced functional multidrug resistance 1 overexpression and doxorubicin sensitivity in acute myeloid leukemic HL-60 cells.
The Journal of pharmacology and experimental therapeutics 2005;312(1):346-54.
2004: Isabelle Hubeek; Elena Litvinova; Godefridus J Peters; Richard Broekhuizen; Eric G Haarman; Dieuwke R Huismans; Jacqueline Cloos; Christian M Zwaan; Gudrun Fleischhack; Ursula Creutzig; G J L Kaspers
The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia.
International journal of oncology 2004;25(6):1823-9.
2004: Ursula Creutzig; Martin Zimmermann; Dirk Reinhardt; Michael Dworzak; Jan Stary; Thomas Lehrnbecher
Early deaths and treatment-related mortality in children undergoing therapy for acute myeloid leukemia: analysis of the multicenter clinical trials AML-BFM 93 and AML-BFM 98.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(21):4384-93.
2004: Isabelle Hubeek; Godefridus J Peters; A J F Broekhuizen; Iannis Talianidis; Antoinette Y N Schouten-Van Meeteren; Elisabeth R van Wering; B Gibson; Ursula Creutzig; G J L Kaspers
Immunocytochemical detection of deoxycytidine kinase in pediatric malignancies in relation to in vitro cytarabine sensitivity.
Nucleosides, nucleotides & nucleic acids 2004;23(8-9):1351-6.
2004: Dirk Reinhardt; Sylke Diekamp; Gudrun Fleischhack; C Corbacioglu; H Jürgens; Michael Dworzak; G J L Kaspers; Ursula Creutzig; Christian M Zwaan
Gemtuzumab ozogamicin (Mylotarg) in children with refractory or relapsed acute myeloid leukemia.
Onkologie 2004;27(3):269-72.
2004: Thomas Lehrnbecher; Domenica Varwig; J Kaiser; Dirk Reinhardt; Thomas Klingebiel; Ursula Creutzig
Infectious complications in pediatric acute myeloid leukemia: analysis of the prospective multi-institutional clinical trial AML-BFM 93.
Leukemia 2004;18(1):72-7.
2003: Georg Hempel; Dirk Reinhardt; Ursula Creutzig; Joachim Boos
Population pharmacokinetics of liposomal daunorubicin in children.
British journal of clinical pharmacology 2003;56(4):370-7.
2003: Christian M Zwaan; Soheil Meshinchi; Jerald P Radich; Anjo J P Veerman; Dieuwke R Huismans; Leonhard Munske; Martina Podleschny; Karel Hählen; Rob Pieters; Martin Zimmermann; Dirk Reinhardt; Jochen Harbott; Ursula Creutzig; G J L Kaspers; Frank Griesinger
FLT3 internal tandem duplication in 234 children with acute myeloid leukemia: prognostic significance and relation to cellular drug resistance.
Blood 2003;102(7):2387-94.
2003: Christian M Zwaan; Dirk Reinhardt; Selim Corbacioglu; Elisabeth R van Wering; Jos P M Bökkerink; Wim J E Tissing; Ulf Samuelsson; Jay Feingold; Ursula Creutzig; G J L Kaspers
Gemtuzumab ozogamicin: first clinical experiences in children with relapsed/refractory acute myeloid leukemia treated on compassionate-use basis.
Blood 2003;101(10):3868-71.
2003: Ursula Creutzig; M Zimmermann; Dirk Reinhardt; T Lehrnbecher
[Analysis of causes of death during intensive chemotherapy according to treatment protocol AML-BFM 93].
Klinische Pädiatrie 2003;215(3):151-8.
2003: Claudia Lanvers; Dirk Reinhardt; Angelika Dübbers; Alexandra Wagner-Bohn; Ursula Creutzig; Joerg Ritter; Joachim Boos
Pharmacology of all-trans-retinoic acid in children with acute promyelocytic leukemia.
Medical and pediatric oncology 2003;40(5):293-301.
2003: Patricia Kaaijk; G J L Kaspers; Elisabeth R van Wering; GJ Broekema; Anne H Loonen; Karel Hählen; Kjeld Schmiegelow; Gritta E Janka-Schaub; Günter Henze; Ursula Creutzig; Anjo J P Veerman
Cell proliferation is related to in vitro drug resistance in childhood acute leukaemia.
British journal of cancer 2003;88(5):775-81.
2002: Christian M Zwaan; G J L Kaspers; Rob Pieters; Karel Hählen; Dieuwke R Huismans; Martin Zimmermann; Jochen Harbott; Rosalyn M Slater; Ursula Creutzig; Anjo J P Veerman
Cellular drug resistance in childhood acute myeloid leukemia is related to chromosomal abnormalities.
Blood 2002;100(9):3352-60.
2002: Dirk Reinhardt; Georg Hempel; Gudrun Fleischhack; A Schulz; Joachim Boos; Ursula Creutzig
[Liposomal daunorubicine combined with cytarabine in the treatment of relapsed/refractory acute myeloid leukemia in children].
Klinische Pädiatrie 2002;214(4):188-94.
2002: Dirk Reinhardt; Claudia Langebrake; Ursula Creutzig; Josef Vormoor; C Brune; M Thorwesten; P Ingiliz; Ondrej Hrusak; Michael Dworzak; Frank Griesinger
[Minimal residual disease in acute myeloid leukemia in children--standardization and evaluation of immunophenotyping in the AML-BFM-98 study].
Klinische Pädiatrie 2002;214(4):179-87.
2002: Dirk Reinhardt; C Thiele; Ursula Creutzig
[Neuropsychological sequelae in children with AML treated with or without prophylactic CNS-irradiation].
Klinische Pädiatrie 2002;214(1):22-9.
2002: Christian M Zwaan; G J L Kaspers; Rob Pieters; Karel Hählen; Gritta E Janka-Schaub; Christina H van Zantwijk; Dieuwke R Huismans; Esther de Vries; Marianne G Rots; Godefridus J Peters; Gerrit Jansen; Ursula Creutzig; Anjo J P Veerman
Different drug sensitivity profiles of acute myeloid and lymphoblastic leukemia and normal peripheral blood mononuclear cells in children with and without Down syndrome.
Blood 2002;99(1):245-51.
2001: Ursula Creutzig; F Berthold; Joachim Boos; G Fleischhack; H Gadner; A Gnekow; Ulrike B Graubner; G Henze; Johann Hermann; P Imbach; Heribert Jürgens; Hartmut Kabisch; Dieter Körholz; Charlotte M Niemeyer; Dirk Reinhardt; Alfred Reiter; Jörg Ritter; Hans J Spaar; Martin Zimmermann
[Improved treatment results in children with AML: Results of study AML-BFM 93].
Klinische Pädiatrie 2001;213(4):175-85.
2001: Ursula Creutzig; J Ritter; Martin Zimmermann; Dirk Reinhardt; J Hermann; F Berthold; Günter Henze; Heribert Jürgens; H Kabisch; Werner Havers; Alfred Reiter; U Kluba; F Niggli; H Gadner
Improved treatment results in high-risk pediatric acute myeloid leukemia patients after intensification with high-dose cytarabine and mitoxantrone: results of Study Acute Myeloid Leukemia-Berlin-Frankfurt-Münster 93.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(10):2705-13.
2001: Marianne G Rots; Rob Pieters; Gerrit Jansen; G J L Kaspers; Christina H van Zantwijk; Paul Noordhuis; Daphne Voorn; Elisabeth R van Wering; Ursula Creutzig; Anjo J P Veerman; Godefridus J Peters
A possible role for methotrexate in the treatment of childhood acute myeloid leukaemia, in particular for acute monocytic leukaemia.
European journal of cancer (Oxford, England : 1990) 2001;37(4):492-8.
2000: Christian M Zwaan; G J L Kaspers; Rob Pieters; NL Ramakers-van Woerden; Monique L den Boer; R Wünsche; M M A Rottier; Karel Hählen; Elisabeth R van Wering; Gritta E Janka-Schaub; Ursula Creutzig; Anjo J P Veerman
Cellular drug resistance profiles in childhood acute myeloid leukemia: differences between FAB types and comparison with acute lymphoblastic leukemia.
Blood 2000;96(8):2879-86.
2000: Ursula Creutzig; Dieter Körholz; Charlotte M Niemeyer; Hartmut Kabisch; Norbert Graf; Alfred Reiter; Hans G Scheel-Walter; Christine Bender-Götze; W Behnisch; Johann Hermann; Georg Mann; Jörg Ritter; Martin Zimmermann
Toxicity and effectiveness of high-dose idarubicin during AML induction therapy: results of a pilot study in children.
Klinische Pädiatrie 2000;212(4):163-8.
2000: Angelika Dübbers; Gudrun Würthwein; Hans-Joachim Müller; Petra Schulze-Westhoff; M Winkelhorst; E Kurzknabe; Claudia Lanvers; Rob Pieters; G J L Kaspers; Ursula Creutzig; J Ritter; Joachim Boos
Asparagine synthetase activity in paediatric acute leukaemias: AML-M5 subtype shows lowest activity.
British journal of haematology 2000;109(2):427-9.
2000: Ursula Creutzig; Dieter Körholz; Charlotte M Niemeyer; K Kabisch; Norbert Graf; Alfred Reiter; Hans G Scheel-Walter; Christine Bender-Götze; W Behnisch; Johann Hermann; Georg Mann; Jörg Ritter; Martin Zimmermann
3 x 14 mg/m2 idarubicin during induction: results of a pilot study in children with AML.
Leukemia 2000;14(2):340-2.
1999: Marianne G Rots; Rob Pieters; Godefridus J Peters; Christina H van Zantwijk; Robert Mauritz; Paul Noordhuis; James Willey; Karel Hählen; Ursula Creutzig; Gritta E Janka-Schaub; G J L Kaspers; Anjo J P Veerman; Gerrit Jansen
Circumvention of methotrexate resistance in childhood leukemia subtypes by rationally designed antifolates.
Blood 1999;94(9):3121-8.
1999: Ulrike B Graubner; Joachim Boos; Ursula Creutzig; Wolfgang Dörffel; M Lakomek; Charlotte Niemeyer; Martin Schrappe; Hans J Spaar; Bernd H Belohradsky
[Antiinfectious prophylaxis in pediatric oncology. Work group "Quality Assurance" of Society for Pediatric Oncology and Hematology (GPOH)].
Klinische Pädiatrie 1999;211(4):347-52.
1999: G J L Kaspers; Christian M Zwaan; Anjo J P Veerman; Marianne G Rots; Rob Pieters; P Bucsky; M Domula; Ulrich Göbel; N Graf; W Havers; Norbert Jorch; K Kabisch; Hans J Spaar; Jörg Ritter; Ursula Creutzig
Cellular drug resistance in acute myeloid leukemia: literature review and preliminary analysis of an ongoing collaborative study.
Klinische Pädiatrie 1999;211(4):239-44.
1999: Ursula Creutzig; Martin Zimmermann; J Ritter; Günter Henze; N Graf; H Löffler; Günther Schellong
Definition of a standard-risk group in children with AML.
British journal of haematology 1999;104(3):630-9.
1999: Henrik Hasle; Maurizio Aricò; Giuseppe Basso; Andrea Biondi; A Cantù-Rajnoldi; Ursula Creutzig; SUSANNA FENU; C Fonatsch; O A Haas; Jochen Harbott; Gabriela Kardos; Gitte B Kerndrup; G Mann; Charlotte M Niemeyer; H Ptoszkova; Jörg Ritter; R Slater; Jan Starý; B Stollmann-Gibbels; A M Testi; Elisabeth R van Wering; Martin Zimmermann
Myelodysplastic syndrome, juvenile myelomonocytic leukemia, and acute myeloid leukemia associated with complete or partial monosomy 7. European Working Group on MDS in Childhood (EWOG-MDS).
Leukemia 1999;13(3):376-85.
1999: Marianne G Rots; Rob Pieters; Godefridus J Peters; Paul Noordhuis; Christina H van Zantwijk; G J L Kaspers; Karel Hählen; Ursula Creutzig; Anjo J P Veerman; Gerrit Jansen
Role of folylpolyglutamate synthetase and folylpolyglutamate hydrolase in methotrexate accumulation and polyglutamylation in childhood leukemia.
Blood 1999;93(5):1677-83.
1999: Monique L den Boer; Rob Pieters; Karin M Kazemier; Gritta E Janka-Schaub; Günter Henze; Ursula Creutzig; G J L Kaspers; Pamela R Kearns; Andrew G Hall; Andrew D J Pearson; Anjo J P Veerman
Different expression of glutathione S-transferase alpha, mu and pi in childhood acute lymphoblastic and myeloid leukaemia.
British journal of haematology 1999;104(2):321-7.
1998: Karsten Stahnke; Joachim Boos; Christine Bender-Götze; Jörg Ritter; Martin Zimmermann; Ursula Creutzig
Duration of first remission predicts remission rates and long-term survival in children with relapsed acute myelogenous leukemia.
Leukemia 1998;12(10):1534-8.
1998: Ursula Creutzig; Jörg Ritter; Joachim Boos; Martin Zimmermann; Christine Bender-Götze; Karsten Stahnke
[Prognosis of children with acute myelocytic leukemia after first relapse].
Klinische Pädiatrie 1998;210(4):207-11.
1998: Ursula Creutzig; Christine Bender-Götze; Jörg Ritter; Martin Zimmermann; B Stollmann-Gibbels; Dieter Körholz; Charlotte Niemeyer
The role of intensive AML-specific therapy in treatment of children with RAEB and RAEB-t.
Leukemia 1998;12(5):652-9.
1998: Monique L den Boer; Rob Pieters; Karin M Kazemier; M M A Rottier; Christian M Zwaan; G J L Kaspers; Gritta E Janka-Schaub; Günter Henze; Ursula Creutzig; Rik J Scheper; Anjo J P Veerman
Relationship between major vault protein/lung resistance protein, multidrug resistance-associated protein, P-glycoprotein expression, and drug resistance in childhood leukemia.
Blood 1998;91(6):2092-8.
1997: Günther Schellong; Marianne Riepenhausen; Ursula Creutzig; J Ritter; J Harbott; Georg Mann; Helmut Gadner
Low risk of secondary leukemias after chemotherapy without mechlorethamine in childhood Hodgkin's disease. German-Austrian Pediatric Hodgkin's Disease Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(6):2247-53.
1997: Charlotte M Niemeyer; M Arico; Giuseppe Basso; Andrea Biondi; A Cantu Rajnoldi; Ursula Creutzig; O Haas; Jochen Harbott; Henrik Hasle; Gitte B Kerndrup; Franco Locatelli; G Mann; B Stollmann-Gibbels; E T van't Veer-Korthof; Elisabeth R van Wering; Martin Zimmermann
Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS)
Blood 1997;89(10):3534-43.
1996: Ursula Creutzig; J Ritter; Josef Vormoor; Wolf-Dieter Ludwig; C Niemeyer; I Reinisch; B Stollmann-Gibbels; Martin Zimmermann; Jochen Harbott
Myelodysplasia and acute myelogenous leukemia in Down's syndrome. A report of 40 children of the AML-BFM Study Group.
Leukemia 1996;10(11):1677-86.
1996: Ursula Creutzig; J Ritter; M Zimmermann; T Klingebiel
[Prognosis of children with chronic myeloid leukemia: a retrospective analysis of 75 patients].
Klinische Pädiatrie 1996;208(4):236-41.
1996: Josef Vormoor; Joachim Boos; Karsten Stahnke; Heribert Jürgens; J Ritter; Ursula Creutzig
Therapy of childhood acute myelogenous leukemias.
Annals of hematology 1996;73(1):11-24.
1995: E Klumper; Rob Pieters; G J L Kaspers; D R Huismans; A H Loonen; M M A Rottier; Elisabeth R van Wering; Anna van der Does-van den Berg; Karel Hählen; Ursula Creutzig
In vitro chemosensitivity assessed with the MTT assay in childhood acute non-lymphoblastic leukemia.
Leukemia 1995;9(11):1864-9.
1995: Ursula Creutzig; J Ritter; Wolf-Dieter Ludwig; C Niemeyer; I Reinisch; B Stollmann-Gibbels; M Zimmermann; Jochen Harbott
[Acute myeloid leukemia in children with Down syndrome].
Klinische Pädiatrie 1995;207(4):136-44.
1994: S Sauter; P Kaatsch; Ursula Creutzig; J Michaelis
[Establishment of a uniform common data set for pediatric oncology. Applied Informatics Study Group of the GPOH (Society of Pediatric Oncology and Hematology)].
Klinische Pädiatrie 1994;206(4):306-12.
1993: Ursula Creutzig; J Ritter; W D Ludwig; J Harbott; H Löffler; Günther Schellong
[Classification of AML by morphologic, immunologic and cytogenetic criteria. Review with reference to subtypes in the AML-BFM-87 study].
Klinische Pädiatrie 1993;205(4):272-80.
1993: Ursula Creutzig; J Ritter; M Zimmermann; Günther Schellong
Does cranial irradiation reduce the risk for bone marrow relapse in acute myelogenous leukemia? Unexpected results of the Childhood Acute Myelogenous Leukemia Study BFM-87.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(2):279-86.
1992: Josef Vormoor; J Ritter; Ursula Creutzig; Joachim Boos; P Heyen; Wolf-Dieter Ludwig; Jochen Harbott; Helmut Löffler; Günther Schellong
Acute myelogenous leukaemia in children under 2 years--experiences of the West German AML studies BFM-78, -83 and -87. AML-BFM Study Group.
The British journal of cancer. Supplement 1992;18():S63-7.
1992: Karsten Stahnke; J Ritter; G Schellong; J D Beck; H Kabisch; F Lampert; Ursula Creutzig
[Treatment of recurrence of acute myeloid leukemia in childhood. A retrospective analysis of recurrence in the AML-BFM-83 study].
Klinische Pädiatrie 1992;204(4):253-7.
1992: Ursula Creutzig; Christine Bender-Götze; T Klingebiel; Wolfram Ebell; W Friedrich; B Stollmann-Gibbels; H Schmidt; Meinolf Suttorp; A Gratwohl; P Heyen
[Comparison of chemotherapy alone with allogeneic bone marrow transplantation in first full remission in children with acute myeloid leukemia in the AML-BFM-83 and AML-BFM-87 studies--matched pair analysis].
Klinische Pädiatrie 1992;204(4):246-52.
1992: Ursula Creutzig; J Ritter; P Heyen; F Berthold; G Henze; H Kabisch; F Lampert; D Niethammer; H Riehm; Günther Schellong
[Effect of cranial irradiation on rate of recurrence in children with acute myeloid leukemia. Initial results of the AML-BFM-87 study. The AML-BFM Study Group].
Klinische Pädiatrie 1992;204(4):236-45.
1992: C Niemeyer; B Stollmann-Gibbels; Wolfram Ebell; G Gaedicke; Ursula Creutzig
[Myelodysplastic diseases in childhood].
Klinische Pädiatrie 1992;204(4):190-7.
1990: Ursula Creutzig; J Ritter; Josef Vormoor; C Eschenbach; Roswita Dickerhoff; S Burdach; H G Scheel-Walter; J Kühl; Günther Schellong
[Transient myeloproliferation and acute myeloid leukemia in infants with Down's syndrome].
Klinische Pädiatrie 1990;202(4):253-7.
1990: Ursula Creutzig; G Niederbiermann; J Ritter; Jochen Harbott; Helmut Löffler; Günther Schellong
Prognostic significance of eosinophilia in acute myelomonocytic leukemia in relation to induction treatment.
Haematology and blood transfusion 1990;33():226-32.
1990: J Ritter; Ursula Creutzig; A Reiter; H Riehm; Günther Schellong
Childhood leukemia: cooperative Berlin-Frankfurt-Münster trials in the Federal Republic of Germany.
Journal of cancer research and clinical oncology 1990;116(1):100-3.
1989: Josef Vormoor; J Ritter; Ursula Creutzig; Günther Schellong
[Incidence and prognostic significance of Auer rods in children with acute myeloid leukemia in the studies AML-BFM-78 and -83].
Klinische Pädiatrie 1989;201(4):227-32.
1989: Ursula Creutzig; J Ritter; G Niederbiermann-Koczy; J Harbott; Günther Schellong
[Prognostic significance of eosinophilia in children with acute myeloid leukemia in the studies AML-BFM-78 and -83].
Klinische Pädiatrie 1989;201(4):220-6.
1988: Ursula Creutzig; J Hofmann; J Ritter; Günther Schellong
[Therapy realization and complications in the BFM-83 therapy study of acute myelogenous leukemia].
Klinische Pädiatrie 1988;200(3):190-9.
1987: Ursula Creutzig; J Ritter; M Budde; Anton Heinz Sutor; G Schellong
Early deaths due to hemorrhage and leukostasis in childhood acute myelogenous leukemia. Associations with hyperleukocytosis and acute monocytic leukemia.
Cancer 1987;60(12):3071-9.
1987: Ursula Creutzig; Karsten Stahnke; H Pollmann; Anton Heinz Sutor; J Ritter; M Budde; G Schellong
The problem of early death in childhood AML.
Haematology and blood transfusion 1987;30():524-9.
1987: J Harbott; M Budde; Ursula Creutzig; R Engel; R Fengler; B Rudolph; Fritz H Lampert
Prognostic meaning of chromosome aberrations in acute lymphocytic leukemia and acute nonlymphocytic leukemia patients of the BFM Study Group.
Haematology and blood transfusion 1987;30():497-503.
1987: W D Ludwig; F Herrmann; A Gatzke; M Budde; Ursula Creutzig; J Ritter; G Schellong
Surface marker analysis by monoclonal antibodies: a valuable technique in childhood acute myeloid leukemia.
Haematology and blood transfusion 1987;30():418-22.
1987: Ursula Creutzig; A Cantù-Rajnoldi; J Ritter; L Romitti; E Odenwald; Valentino Conter; Hansjörg Riehm; G Masera
Myelodysplastic syndromes in childhood. Report of 21 patients from Italy and West Germany.
The American journal of pediatric hematology/oncology 1987;9(4):324-30.
1987: Ursula Creutzig; J Ritter; M Budde; H Jürgens; Hansjörg Riehm; G Schellong
Treatment results in childhood AML, with special reference to the German studies BFM-78 and BFM-83.
Haematology and blood transfusion 1987;31():30-4.
1987: Ursula Creutzig; J Ritter; Hansjörg Riehm; M Budde; G Schellong
The childhood AML studies BFM-78 and -83: treatment results and risk factor analysis.
Haematology and blood transfusion 1987;30():71-5.
1986: Ursula Creutzig; J Ritter; M Budde; Hansjörg Riehm; Günter Henze; Fritz H Lampert; V Gerein; S Müller-Weihrich; D Niethammer; Hans J Spaar
[Current results of cooperative AML therapy studies in children: BFM-78 and 83].
Klinische Pädiatrie 1986;198(3):183-90.
1986: R Fengler; E Baumgarten; S Buchmann; Ursula Creutzig; J Harbott; R Ludwig; Günter Henze
[Biclonal leukemia O-ALL/AMoL) with 11;19 translocation and trisomy X in an 8-month-old girl].
Klinische Pädiatrie 1986;198(3):178-82.
1985: W Hiddemann; J Ritter; B Wörmann; M Budde; Ursula Creutzig; G Schellong; T Büchner; Hansjörg Riehm
[DNA aneuploidy in children with acute leukemia: I. Incidence and clinical significance within the scope of the BFM studies].
Klinische Pädiatrie 1985;197(3):215-20.
1985: Ursula Creutzig; W Brandeis; V Gerein; J Ritter; B Stollmann; Hartmut Kabisch; D Niethammer; G Schellong
[Adult form of chronic myelogenous leukemia in childhood--a retrospective analysis of 20 patients].
Klinische Pädiatrie 1985;197(3):203-6.
1985: Ursula Creutzig; J Ritter; Hansjörg Riehm; H J Langermann; Günter Henze; Hartmut Kabisch; D Niethammer; H Jürgens; B Stollmann; U Lasson
Improved treatment results in childhood acute myelogenous leukemia: a report of the German cooperative study AML-BFM-78.
Blood 1985;65(2):298-304.
1985: J Ritter; Ursula Creutzig; Hansjörg Riehm; W Brandeis; V Gerein; G Prindull; M Rister; G Schellong
Improved treatment results in childhood acute myelogenous leukemia: an update of the German cooperative study AML-BFM-78.
Haematology and blood transfusion 1985;29():82-3.
1984: Ursula Creutzig; A Schaaff; J Ritter; A Jobke; U Kaufmann; G Schellong
[Acute myelogenous leukemia in children under 2 years of age: studies and treatment results in 23 children in the AML therapy study BFM-78].
Klinische Pädiatrie 1984;196(3):130-4.
1983: Ursula Creutzig; J Ritter; H J Langermann; Hansjörg Riehm; Günter Henze; D Niethammer; Heribert Jürgens; B Stollmann; U Lasson; Hartmut Kabisch; W Wahlen; H Löffler; G Schellong
[Acute myelogenous leukemia in children: results of the cooperative BFM-78 therapy study after 3 3/4 years].
Klinische Pädiatrie 1983;195(3):152-60.
1983: Ursula Creutzig; G Schellong; J Ritter; A H Sutor; Hansjörg Riehm; H J Langermann; A Jobke; H Kabisch
Improved results in treatment of acute myelogenous leukemia in children--report of the German cooperative AML study BFM-78.
Haematology and blood transfusion 1983;28():46-50.